A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames
Backed by senior members of the founding family, the traditionalists among Takeda’s investors have made their last stand in the fight against remaking the 237-year-old company as a global heavyweight.
They lost.
Opposition was rendered futile as a large majority of the Japanese drugmaker’s shareholders ultimately agreed to sanction the $62 billion takeover of Britain’s rare disease drug specialist Shire.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
